How much heart disease is caused by body fat? | Robert Eckel | EP#403
Robert Eckel discusses the relationship between body fat and cardiometabolic disease, stating that 50-67% of people with cardiometabolic diseases have obesity as a major contributing factor. However, he emphasizes that a significant minority of the population develop conditions like heart failure, coronary heart disease, and type 2 diabetes without being obese.
Summary
In this episode, Robert Eckel addresses the question of what percentage of cardiometabolic disease is driven by excessive body fat. He explains that while obesity is a significant contributor to many cardiometabolic conditions, it is not the only factor. Eckel notes that medical research has updated its understanding to recognize that some people without obesity still develop serious diseases traditionally associated with excess body weight. These conditions include heart failure, coronary heart disease, and type 2 diabetes. According to Eckel's assessment, approximately 50-67% of people with cardiometabolic diseases have obesity as a major contributing factor. This means that a considerable minority—roughly one-third to one-half—of individuals with these diseases are not obese, indicating that other factors beyond body fat play important roles in disease development. This distinction is clinically important as it suggests that cardiometabolic disease prevention and treatment cannot rely solely on addressing obesity.
Key Insights
- Approximately 50-67% of people with cardiometabolic diseases have obesity as a major contributing factor
- A significant minority of the population develop cardiometabolic diseases like heart failure and coronary heart disease without excess body weight
- Type 2 diabetes can occur occasionally in normal weight persons without excess body weight
- Heart failure and coronary heart disease are not exclusively caused by obesity despite their strong association
- One-third to one-half of people with cardiometabolic diseases are not obese, suggesting other contributing factors exist beyond body fat
Topics
Transcript
[0:00] If you were to put a number on it, what percentage of cardiometabolic disease would you say is driven by excessive body fat? >> We updated to look at the percentage of people with existing, what we call clinical obesity illnesses that do not have obesity. So, that means that some of the diseases like heart failure and coronary heart disease, type 2 diabetes can occur occasionally in normal weight person without excess body weight. There's a significant minority of the population that have these same diseases that are not obese. So, I would say 50% to 2/3 of people with cardiometabolic [0:32] diseases have obesity as a major contributing factor. >> [sighs]
Full transcript available for MurmurCast members
Sign Up to AccessMore from The Proof with Simon Hill
MASH vs. MASLD: Which Medications Are Actually FDA Approved for Weight Loss? | Dr Mauricio Gonzalez
Dr. Mauricio Gonzalez clarifies that the United States has two FDA-approved medications specifically for MASH (metabolic dysfunction-associated steatohepatitis): resmetirom and semaglutide (Wegovy). However, for pure MASLD (metabolic dysfunction-associated fatty liver disease) without inflammation, there are currently no FDA-approved medications.
How Effective Are Weight Loss Drugs? The Risk and Limitations You Should Know About | EP#422
GLP-1 weight loss drugs are significantly more effective than diet alone, with 90-95% of clinical trial participants losing weight, but real-world non-response rates reach 20%. However, discontinuation rates are high (75% within 18 months), and without proper nutrition and exercise support, users risk losing up to 40% muscle mass while regaining primarily fat, creating sarcopenic obesity.
What Is the MIND Diet? (You Don't Have to Eat Perfectly) | Dr Terry Simpson
The MIND diet combines Mediterranean and DASH diets, focusing on increased fruits, vegetables, legumes, whole grains, and healthy fats while reducing red meat. Dr. Simpson emphasizes that perfection isn't required—studies show people scoring around 12.5 out of 15 points experienced the most benefits.
How Does HeartFlow's AI Analyze Your Heart Scan? | Dr Campbell Rogers | EP#426
Dr. Campbell Rogers explains HeartFlow's AI analysis process for heart scans, emphasizing that the company assesses image quality first, rejecting approximately 2-3% of scans that are too fuzzy. He highlights that scanner type, procedure techniques, and medications used at each site significantly impact image quality and the ability to track disease progression over time.
Muscle Loss Fix: Why Movement Beats More Protein | Simon Hill
Protein is often overemphasized in discussions about muscle loss, but the real driver of sarcopenia in America is sedentary lifestyle and lack of resistance training stimulus. Most people consume sufficient protein; the limiting factor is movement and strength training, not dietary protein intake.